QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=7745041CF132C1F41D203F9E5618A0A6;jsessionid=FD4451ED48614C439BBB428BB84CA546;jsessionid=133964EBE041FD30A1D1968F5C6DC915;jsessionid=B0E08EF4E1DF597893822A1E7020FE8A;jsessionid=2B88414E5320C384652DE88D9AFC43F7;jsessionid=9C9B0DB6D28E01996450B10F37D522E0 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=7745041CF132C1F41D203F9E5618A0A6;jsessionid=FD4451ED48614C439BBB428BB84CA546;jsessionid=133964EBE041FD30A1D1968F5C6DC915;jsessionid=B0E08EF4E1DF597893822A1E7020FE8A;jsessionid=2B88414E5320C384652DE88D9AFC43F7;jsessionid=9C9B0DB6D28E01996450B10F37D522E0